ResMed Competitive Intelligence & Landscape

ResMed (resmed.com) is a global leader in sleep health and respiratory care, dedicated to pioneering innovative technology that helps people sleep, breathe, and live better [resmed.com]. Established over 35 years ago, the company focuses on creating life-changing health technologies that people love, operating in 140 countries [resmed.com].

ResMed is headquartered at 9001 Spectrum Center Blvd, San Diego, CA 92123, United States [investor.resmed.com/sec-filings/all-sec-filings/content/0000943819-25-000035/0000943819-25-000035.pdf].

The company's core products and services revolve around cloud-connected medical devices and AI-powered digital health solutions for conditions such as sleep apnea, COPD, and other chronic respiratory diseases [resmed.com/en-us/about-us/, investor.resmed.com/company-information/about-us]. Their offerings include CPAP machines, CPAP masks, and CPAP supplies and replacement parts, forming complete systems for sleep apnea treatment [resmed.com].

ResMed also provides digital support tools like the myAir app for CPAP therapy and a 24/7 virtual assistant named Dawn for product and service support [resmed.com, resmed.com/en-us/contact-us/].

ResMed's target market includes consumers and patients suffering from sleep and respiratory issues, as well as healthcare professionals, home medical equipment (HME) providers, and sleep labs [resmed.com/en-us/contact-us/]. The company emphasizes empowering millions globally to live happier, healthier lives through personalized, accessible, and effective home healthcare solutions [investor.resmed.com/company-information/about-us]. They have over 12 million 100% cloud-connectable devices worldwide, showcasing their commitment to digital innovation in out-of-hospital care settings [careers.resmed.com/what-we-do/our-global-businesses/].

ResMed (resmed.com) specializes in sleep health, offering a range of CPAP and APAP machines, masks, and related supplies. The company's product intelligence reveals various bundles and individual components available for purchase. For instance, the AirSense 10 Autoset CPAP Machine + AirFit X30i Mask Bundle is priced at $1,271.00, while a similar bundle with the AirFit P10 Mask costs $1,119.00 [source] [source]. A more portable option, the AirMini AutoSet CPAP Machine + AirFit P10 Mask Pack, is available for $1,084.00 [source]. Free ground shipping is provided for orders over $50 on their e-shop [source].

ResMed also offers the AirSense 11 series, which includes both APAP and CPAP machines designed for easier therapy initiation and adherence [source]. The AirSense 11 AutoSet complete device package is listed at £766.00 plus VAT in the UK, including an integrated humidifier and heated tube, but excluding a mask [source]. Another advanced option is the AirCurve 11 Bilevel machine, which provides greater pressure support and includes digital health solutions like myAir™ [source].

A significant free feature offered by ResMed is myAir™, a complimentary online support program and app that syncs with mobile or web devices. This program provides users with a nightly sleep score, coaching, and other resources to help them stay on track with their therapy [source]. The AirSense 10 series, a widely used line of CPAP and APAP machines, gives users access to myAir™ [source]. Similarly, the AirCurve 11 devices also incorporate myAir™, along with Care Check-In and Personal Therapy Assistant [source].

For those seeking fixed-pressure devices, the ResMed AirSense 11 Elite is a premium option that integrates a heated humidifier, wireless connectivity, and advanced event detection. This model also boasts enhanced digital health technology to support patients throughout their therapy journey [source].

ResMed also offers the AirCurve 10 ST, a bilevel therapy machine known for its compact design, quiet operation, and features like Climate Control with a built-in HumidAir™ humidifier for enhanced comfort [source].

ResMed (resmed.com), a leader in sleep and respiratory healthcare technology, actively recruits for various roles, indicating a steady focus on expanding its global operations and product development. The company offers a wide range of career opportunities across all business units, with a dedicated careers portal showcasing recently opened jobs and avenues for early career professionals and graduates [careers.resmed.com/careers/early-careers/]. This sustained recruitment effort underscores ResMed's commitment to innovation and maintaining its position in the health technology sector.

ResMed's hiring patterns highlight strategic areas of growth within the company. There's a notable emphasis on Product Development, including teams focused on Consumer Hardware, Consumer Digital & Provider, Health Platform, Product Marketing, and Product Operations [careers.resmed.com/careers/global-product-management/]. These hiring trends suggest a strategy centered on enhancing its technological offerings and digital health solutions, aligning with its mission to revolutionize global health through innovative sleep and respiratory care.

The company also frequently seeks talent for its Product Development Team, featuring roles like Graduate Verification & Validation Engineer, and for its Strategy teams [careers.resmed.com/careers/product-development-team/]. The diverse range of available positions, from technical engineering roles to product management and marketing, reflects a holistic approach to growth. While specific layoff information is not detailed in the provided sources, the consistent advertisement of global career opportunities across various teams points towards a healthy and expanding workforce at ResMed [careers.resmed.com].

ResMed (resmed.com), a Delaware corporation formed in March 1994, demonstrates a strong financial performance, particularly in its Sleep and Breathing Health products and Residential Care Software segments [https://investor.resmed.com/sec-filings/content/0000943819-26-000025/0000943819-26-000025.pdf]. For the nine months ended March 31, 2026, ResMed reported total net revenue of $4,189,796, up from $3,798,334 for the same period in 2025 [https://investor.resmed.com/sec-filings/content/0000943819-26-000025/0000943819-26-000025.pdf]. Specifically, revenue from Sleep and Breathing Health products reached $3,685,900, and Residential Care Software generated $503,896 during this period [https://investor.resmed.com/sec-filings/content/0000943819-26-000025/0000943819-26-000025.pdf]. The company's fiscal year ends on June 30th [https://investor.resmed.com/quarterly-earnings/financial-results].

In the third quarter of fiscal year 2026, ResMed announced an 11% increase in revenue to $1.4 billion, reflecting an 8% rise on a constant currency basis [https://newsroom.resmed.com/news-releases/news-details/2026/Resmed-Inc--Announces-Results-for-the-Third-Quarter-of-Fiscal-Year-2026/default.aspx]. The company achieved a GAAP gross margin of 62.2% and a non-GAAP gross margin of 62.8%, both up by 290 basis points [https://newsroom.resmed.com/news-releases/news-details/2026/Resmed-Inc--Announces-Results-for-the-Third-Quarter-of-Fiscal-Year-2026/default.aspx]. GAAP income from operations saw a 17% increase, while non-GAAP income from operations grew by 18% [https://newsroom.resmed.com.au/news-releases/news-details/2026/Resmed-Inc--Announces-Results-for-the-Third-Quarter-of-Fiscal-Year-2026/default.aspx]. Diluted earnings per share were $2.74 (GAAP) and $2.86 (non-GAAP), and operating cash flow stood at $554 million, with $262 million returned to shareholders through share repurchases and dividends [https://newsroom.resmed.com.au/news-releases/news-details/2026/Resmed-Inc--Announces-Results-for-the-Third-Quarter-of-Fiscal-Year-2026/default.aspx].

For the first quarter of fiscal year 2026, ResMed reported a 9% revenue increase to $1.3 billion, an 8% increase on a constant currency basis [https://investor.resmed.com/news-events/press-releases/detail/412/resmed-inc-announces-results-for-the-first-quarter-of-fiscal-year-2026]. Gross margin improved by 290 basis points to 61.5%, with non-GAAP gross margin at 62.0% [https://investor.resmed.com/news-events/press-releases/detail/412/resmed-inc-announces-results-for-the-first-quarter-of-fiscal-year-2026]. Income from operations rose by 15%, and non-GAAP income from operations by 19% [https://investor.resmed.com/news-events/press-releases/detail/412/resmed-inc-announces-results-for-the-first-quarter-of-fiscal-year-2026]. Diluted earnings per share were $2.37 (GAAP) and $2.55 (non-GAAP), with an operating cash flow of $457 million [https://investor.resmed.com/news-events/press-releases/detail/412/resmed-inc-announces-results-for-the-first-quarter-of-fiscal-year-2026].

In terms of mergers and acquisitions, ResMed acquired VirtuOx in May 2025 [https://investor.resmed.com/sec-filings/content/0000943819-25-000035/rmd-20250630.htm].

VirtuOx is a software-enabled independent diagnostic testing facility (IDTF) that provides technology solutions for in-home and remote testing services related to sleep, respiratory, and cardiac health [https://investor.resmed.com/sec-filings/content/0000943819-25-000035/rmd-20250630.htm]. As of August 4, 2025, ResMed had 146,414,839 shares of Common Stock outstanding [https://investor.resmed.com/sec-filings/content/0000943819-25-000035/rmd-20250630.htm].

ResMed (resmed.com) actively participates in and hosts various events, including significant industry conferences, investor presentations, and educational initiatives. The company is a regular presence at the SLEEP annual meeting, such as SLEEP 2025 held in Seattle, Washington, from June 7-11, 2025, where they focused on OSA diagnostic innovation and hosted a panel discussion on PAP therapy.

ResMed also participated in SLEEP 2026, presenting new research on advancing sleep health through innovation in screening, diagnosis, and personalized care [https://newsroom.resmed.com/news-releases/news-details/2026/Resmed-at-SLEEP-2026-Advancing-Sleep-Health-Through-Innovation-in-Screening-Diagnosis-and-Personalized-Care--2026-A46lYSiMDw/default.aspx].

In addition to medical conferences, ResMed engages with the financial community through investor events and presentations. Notable participations include the J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco, CA [https://investor.resmed.com/news-events/events-presentations/event-detail/20260112-j-p-morgan-healthcare-conference], and the William Blair Growth Stock Conference on June 2, 2026, where their chairman and CEO, Mick Farrell, and CFO, Aaron Bloomer, attended [https://investor.resmed.com/news-events/events-presentations/event-detail/20260602-william-blair-growth-stock-conference]. The company also holds earnings calls, such as their Fourth Quarter Fiscal Year 2026 Earnings Call on August 6, 2026 [https://investor.resmed.com/news-events/events-presentations].

ResMed also provides educational resources through initiatives like the ResMed Academy Online, which offers free access to materials for continuing education on breathing disorder treatments [https://www.resmed.com/en-us/health-professionals/resources/training/resmed-academy-online/]. These training resources are designed for healthcare professionals and include e-Learning modules and various programs to support patient care [https://www.resmed.com/en-us/health-professionals/resources/training/].